Monte Rosa Therapeutics (GLUE)
(Delayed Data from NSDQ)
$12.43 USD
+0.11 (0.89%)
Updated Oct 28, 2025 04:00 PM ET
After-Market: $12.42 -0.01 (-0.08%) 7:58 PM ET
4-Sell of 5 4
D Value B Growth B Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
GLUE 12.43 +0.11(0.89%)
Will GLUE be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for GLUE based on the 1-3 month trading system that more than doubles the S&P 500.

Zacks News for GLUE
Monte Rosa's Stock Gains on Signing $5.7B Licensing Deal With Novartis
Monte Rosa Therapeutics (GLUE) Soars 44.1%: Is Further Upside Left in the Stock?
GLUE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Tops Revenue Estimates
Certara, Inc. (CERT) Q2 Earnings Miss Estimates
Wall Street Analysts Think Monte Rosa Therapeutics (GLUE) Could Surge 222.16%: Read This Before Placing a Bet
Other News for GLUE
GLUE makes New 52 Week Closing High on October 27
Monte Rosa Therapeutics Advances MRT-2359 in MYC-Driven Cancer Study
Monte Rosa Therapeutics Advances with MRT-8102: A Promising Phase 1 Study
New 52 Week Closing High appears for GLUE after 7.32% move
Is GLUE gaining bullish strength? Pocket Pivot shows up after rallying 11.02%